Bone Mineral Density After Transitioning From Denosumab to Alendronate

CONTEXT: There are few studies on patients transitioning from denosumab to bisphosphonates. OBJECTIVE: To investigate patient characteristics and changes in bone mineral density (BMD) after transitioning from denosumab to alendronate. DESIGN: Randomized, open-label, 2-year crossover Denosumab Adhere...

Descripción completa

Detalles Bibliográficos
Autores principales: Kendler, David, Chines, Arkadi, Clark, Patricia, Ebeling, Peter R, McClung, Michael, Rhee, Yumie, Huang, Shuang, Stad, Robert Kees
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Online Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112973/
https://www.ncbi.nlm.nih.gov/pubmed/31665314
http://dx.doi.org/10.1210/clinem/dgz095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112973/
https://www.ncbi.nlm.nih.gov/pubmed/31665314
http://dx.doi.org/10.1210/clinem/dgz095

Ejemplares similares